Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292943 | 0.87 | SMN1; SMN2 (0.61) | GAAMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL2293410 | 0.85 | MAPT (0.48) | GAAMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL2293586 | 0.83 | MAPT (0.53) | GAAMAPTTP53SMN1; SMN2ADORA1 | |
| SCHEMBL2290049 | 0.83 | MAPT (0.48) | GAAMAPTTP53SMN1; SMN2ADORA1 | |
| SCHEMBL2810374 | 0.81 | GAA (0.66) | GAAMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL2288504 | 0.81 | GAA (0.54) | GAAMAPTTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL2294046 | 0.81 | SMN1; SMN2 (0.53) | GAAMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL2288371 | 0.79 | MAPT (0.46) | GAAMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL2289678 | 0.79 | GAA (0.54) | GAAMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL2287174 | 0.79 | GAA (0.44) | GAAMAPTTP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | claimed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | claimed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | claimed |
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | Merck Patent Gesellschaft Beschrankter Haftung (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2009049731-A1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249151-A1 | IMIDAZO 1, 2-A PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | TYMS, CCNT1, INSR | GAA 1202/4885MAPT 3889/4885TP53 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.